2 May 2023 - Aurinia Pharmaceuticals today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of Lupkynis (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V (including mixed classes III/V and IV/V) lupus nephritis, a serious complication of systemic lupus erythematosus. 

In addition, we have received Orphan Drug designation in Switzerland, granting 15 years of drug exclusivity protection in association with approval.

Read Aurinia Pharmaceuticals press release